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Abstract
Following the recent discovery that heme proteins can catalyze the cyclopropanation of styrenyl 
olefins with high efficiency and selectivity, interest in developing new enzymes for a variety of 
non-natural carbene transfer reactions has burgeoned. The fact that diazo compounds and other 
carbene precursors are known mechanism-based inhibitors of P450s, however, led us to investigate 
if they also interfere with this new enzyme function. We present evidence for two inactivation 
pathways that are operative during cytochrome P450-catalyzed cyclopropanation. Using a 
combination of UV-Vis, mass spectrometry, and proteomic analyses, we show that the heme 
cofactor and several nucleophilic side chains undergo covalent modification by ethyl diazoacetate 
(EDA). Substitution of two of the affected residues with less-nucleophilic amino acids led to a 
more than two-fold improvement in cyclopropanation performance (total TTN). Elucidating the 
inactivation pathways of heme protein-based carbene transfer catalysts should aid in the 
optimization of this new biocatalytic function.
Graphical abstract
*Corresponding Author. frances@cheme.caltech.edu.†Present Addresses
Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458.‡H.R and R.D.L. contributed equally.
ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website.
Supplementary figures, methods, and general procedure (PDF)
HHS Public Access
Author manuscript
J Am Chem Soc. Author manuscript; available in PMC 2017 September 28.
Published in final edited form as:
J Am Chem Soc. 2016 September 28; 138(38): 12527–12533. doi:10.1021/jacs.6b06823.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Over the past few years, we1 and others2 have reported that engineered P450 enzymes and 
other heme proteins can catalyze non-natural carbene transfer reactions, e.g. olefin 
cyclopropanation (Figure 1A), with high efficiency and selectivity. The proposed catalytic 
cycle initiates by reduction of the ferric enzyme to the ferrous counterpart which then reacts 
with a diazo molecule to form an iron carbenoid intermediate. Transfer of the carbene 
fragment to a second substrate forms product and regenerates the active ferrous enzyme. 
Even though the formation of iron carbenoids in P450s has been described in the 
literature,3–6 our report in 20131a was the first example of their use in productive enzymatic 
catalysis. Indeed, P450s were reported to undergo suicide inactivation in the presence of 
halothane3 and CCl44, whereby a putative iron carbenoid led to covalent modification of the 
enzymes and irreversible loss of activity. Similarly, the decomposition of 3-[[2-(2,4,6-
trimethylphenyl)thio]ethyl]-4-methylsydnone by rat liver P450 was proposed to proceed via 
an iron carbenoid intermediate that reacted with the heme cofactor to form N-
vinylprotoporphyrin IX.5
Because understanding inactivation pathways can facilitate development of more stable and 
efficient enzymes,7 we investigated whether the P450-derived ‘carbene transferase’ is 
inactivated by mechanisms similar to the suicide inactivation induced by iron carbenoid 
formation in native P450s. Covalent modification of the heme cofactor or protein side chains 
by the reactive carbenoid intermediate (Figure 1B) would compete with product formation 
and ultimately destroy the catalyst. Our goal is to understand the mechanism of inactivation 
and delay or circumvent it by engineering the protein sequence.
Results
EDA-Induced Inactivation of a P450-Based Cyclopropanation Enzyme
We previously discovered that substitution of the proximal cysteine ligand with histidine in 
cytochrome P450-BM3 led to a highly active cyclopropanation catalyst.1c This finding 
enabled the engineering of a histidine-ligated P450 (BM3-HStar: P450-BM3 V78M L181V 
T268A C400H L437W) that catalyzes the cyclopropanation of phenylacrylamide 1 in a 
highly stereoselective fashion en route to the synthesis of levomilnacipran, an FDA-
approved antidepressant. During efforts to scale up the E. coli whole-cell catalyst expressing 
BM3-HStar, we observed a substantial decrease in the yield and selectivity of the reaction at 
high substrate concentrations. While the reaction provided high yield (92%) and selectivity 
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(92% ee) at 10 mM substrate 1 concentration (20 mM EDA), we found that it afforded only 
28% yield and 50% ee at 50 mM loading (100 mM EDA) (Scheme 1) and was completely 
non-stereoselective at 150 mM (300 mM) loading. This observation led us to believe that an 
inactivation pathway was interfering with selectivity and preventing further conversion at 
higher concentrations of olefin and EDA.
We chose to investigate inactivation of the isolated BM3-HStar enzyme in order to avoid 
possible complications from cellular components. From control experiments, we noted that 
purified enzyme8 that was pre-incubated with EDA in the absence of Na2S2O4 retained 
virtually all of its catalytic activity, whereas pre-incubation with EDA and reductant led to 
rapid inactivation (Figure S1). The fact that inactivation requires reductant suggests a 
mechanism that involves more than simple EDA binding and instead implies a pathway that 
generates a reactive species through reaction of the ferrous heme with the diazo compound, 
consistent with the observation that P450-catalyzed cyclopropanation proceeds from the 
ferrous state.1,9 Thus, we suspected a mechanism-based inactivation pathway whereby the 
reactive iron carbenoid species undergoes undesired side reactions with the enzyme. In the 
presence of the olefin substrate these side reactions could compete with productive 
cyclopropanation, eventually leading to complete catalyst inactivation.
Extent of Heme Cofactor Modification
Previous reports of mechanism-based P450 inactivation indicate that carbene precursors can 
lead to covalent modification of the heme prosthetic group or protein side 
chain(s).3–6,10,11,12 In particular, Ortiz de Montellano and co-workers observed porphyrin 
modification in the reaction of P450 and model Fe-porphyrin complexes with 3-[[2-(2,4,6-
trimethylphenyl)thio]ethyl]-4-methylsydnone5 or diazoacetophenone11 and proposed an 
intramolecular carbene insertion reaction to account for their observations. To investigate 
whether an analogous pathway is operative in our system, we analyzed the porphyrins from 
the reaction of EDA and 1 using purified BM3-HStar and quenched after 15 s and 1 min. 
After extraction from the reaction mixture, the crude organics were analyzed by liquid 
chromatography-mass spectrometry (LC-MS) using detection at 330 nm to minimize 
background signal. In agreement with the observed dependence of enzyme inactivation on 
presence of the reductant, extracts from reaction mixture that did not contain Na2S2O4 
yielded a single species with a mass spectrum and retention time that correspond to 
unmodified Fe-protoporphyrin IX (Fe-PPIX) cofactor, as determined by LC-MS analysis of 
authentic standard (Figure 2). However, the crude extracts obtained after 15 s of reaction of 
1 and EDA using reduced BM3-HStar showed diminished signal for Fe-PPIX and the 
presence of additional species. Strikingly, no unmodified Fe-PPIX remained in the reaction 
mixture quenched after 1 min. Similar analyses performed with other heme protein-based 
carbene transfer catalysts, myoglobin (Mb) mutant H64V V68A2b and a Ser-ligated P450-
BM3,1b also revealed loss of Fe-PPIX (See Supporting Information, Figure S2 and S3).
Thin-layer chromatography (TLC) analysis of the reaction mixture indicated the presence of 
a new red-fluorescent band, which was subsequently purified by preparative TLC and 
analyzed by UV-Vis spectroscopy and mass spectrometry. Absorption spectra obtained for 
the isolated porphyrin species showed that it is distinct from PPIX, both as the free 
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porphyrin (Figure S4) and as the Zn complex (Figure 3). The absorption spectrum of the 
modified porphyrin after complexation with Zn2+ yielded a Soret peak at 430 nm with a 
slight shoulder, which is a characteristic feature of N-alkylprotoporphyrin derivatives.5 
Furthermore, the mass spectrum of the isolated porphyrin exhibited two major peaks with 
m/z of 735.3374 and 821.3753, corresponding to loss of Fe3+ and addition of two and three 
ethyl acetylidene fragments (C4H6O2, m/z = 86.1 Da) to the heme cofactor, respectively. 
These lines of evidence, together with previous literature on P450 cofactor 
modification,5,11,13 point to N-alkylation of the cofactor during the cyclopropanation 
reaction.
Evidence for Modification of Protein Side Chains and Resulting Structural Changes
Given the precedent of protein side chain alkylation during oxidation of acetylenic 
compounds,10 we investigated whether a similar phenomenon occurs during the enzyme-
catalyzed cyclopropanation reaction. To this end, cyclopropanation was performed with 
purified BM3-HStar, quenched after 15 s, and the crude reaction mixture was submitted to 
mass spectrometry (MS) analysis. Extreme heterogeneity of the enzyme could already be 
observed (Figure S5). Deconvolution of the mass spectrum afforded multiple species with 
molecular weights that correspond to integer number additions of the carbene fragment (86 
Da). Under the denaturing conditions used for MS analysis, the heme cofactor is extruded 
from the protein. Thus, any observed mass difference in the spectra can be attributed solely 
to modification of the polypeptide chain.
Circular dichroism (CD) spectroscopy of EDA-treated enzyme also showed changes relative 
to unreacted enzyme in the far-UV region (Figure 4). We noted reduced molar ellipticity at 
222 nm, which suggests decreased α-helical content and increased random coil content of 
the protein. Taking into account both the MS and CD spectral observations, we propose a 
model wherein EDA modifies the cofactor and multiple protein side chains, leading to 
disruption of secondary structures and partial unfolding. Comparison of these data and LC-
MS observation of cofactor modification suggest that the side chain and porphyrin 
alkylations happen on similar time scales, although we cannot determine the exact order of 
events.
Identification of Modified Residues
To identify the residues that are modified during the initial stages of the reaction, protein 
from the crude cyclopropanation reaction mixture after 5 s was analyzed by trypsin digestion 
followed by tandem LC-MS/MS analysis. From this analysis (Figure 5), we observed 
modifications (underlined residues indicate the site of modification) on peptide fragments 
EACDESRFDK (residues 60–69), NLSQALKFMR (residues 70–79), 
DFAGDGLFTSWTHEK (residues 80–94), and AHNILLPSFSQQAMK (residues 99–113). 
Modifications were addition of a C4H6O2 fragment (86.1 Da), corresponding to the ethyl 
acetylidene moiety, onto residues C62, S72, K76, R79, H92, and H100. We also observed 
modification of residue K69 on fragment FDKNLSQALK (residues 67–76) in samples taken 
at later time points. Control experiments with CO-treated enzyme (inactive for 
cyclopropanation) revealed much-diminished signals for modified peptides during the 
proteomic analysis, again suggesting that the iron carbenoid generated from the ferrous 
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heme is responsible for the modifications. That the affected residues are all nucleophilic in 
nature is consistent with the proposed electrophilic character of the carbenoid species.14 
Modifications presumably occur by way of O–, N–, and S– alkylation by the carbene 
fragment.
In the absence of a crystal structure for His-ligated P450-BM3, the crystal structure of wild-
type (WT) BM3 (PDB ID: 2IJ2) was used to map the locations of these residues relative to 
the heme cofactor (Figure 6). To our surprise, other than K69, which makes a polar contact 
with the propionate moiety of the heme cofactor, all the alkylated residues are more than 10 
Å away from the iron center. One possible explanation is that the Hstar active site is devoid 
of nucleophilic residues, and that all likely alkylation targets are distant. It is worth noting, 
however, that residues S72, K76, R79 are situated in the B’-helix and H92 is in the B’/C 
loop. The B’-helix has been proposed as an important recognition site15 that controls 
substrate specificity in P450s. It has also been shown crystallographically that a single 
mutation (F81L) in this region can effect its collapse towards the active site.16 Moreover, our 
recent report17 on the X-ray crystal structure of His-ligated CYP119 shows notable 
rearrangements in the protein to compensate for non-native ligation, including unresolved 
portions in the B’- and F-helices and increased disorder in the C-helix. If similar 
rearrangements occur upon mutation of the axial residue from Cys to His in P450-BM3, it is 
possible that the region where S72, K76, R79, and H92 reside undergoes large-scale 
movements that bring them closer to the active site. Furthermore, the P450s possess 
remarkable structural plasticity,18 and iron carbenoid formation could also induce structural 
and dynamic changes that bring this region in closer contact. In addition to the possibility 
that structural plasticity accounts for the distance of the alkylated sites from the iron center, 
recent computational studies by Khade et al.14a also invoked a dative bond from the carbene 
moiety to Fe, which could implicate a diffusible carbene species in the active site and might 
account for the observed alkylation pattern.
The remaining three alkylated residues also deserve mention, as we surmise that they would 
play vital roles in maintaining the folded structure of P450-BM3. As previously noted, K69 
is involved in a polar contact with the heme prosthetic group (Figure S7). H100 is implicated 
in a hydrogen bonding interaction with the FMN domain of the fused reductase partner and 
is conserved as a basic amino acid residue in P450s.19 Mutation of C62 in P450-BM3 has 
been reported to lower thermostability.20 Thus, modifications of these residues could result 
in disruption of key interactions and loss of structural integrity.
Site-directed Mutagenesis of Modified Residues Improves Catalyst Performance
The observations outlined above indicate that these modifications have deleterious effects on 
the secondary structure of the enzyme and the efficiency of the cyclopropanation reaction. 
We hypothesized that even though BM3-HStar will eventually be inactivated through 
modification of the heme prosthetic group, mutations of the alkylated residues to attenuate 
their nucleophilicity might better preserve structure and function during the reaction and, 
ultimately, improve carbene transfer efficiency to the substrate (measureable in terms of total 
turnover number to product). We therefore created seven single variants of BM3-HStar in 
which the alkylated residues were replaced with their non-nucleophilic isosteres. This design 
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entails mutation of His to Asn (mutations H92N and H100N), Arg to Gln (mutation R79Q), 
Cys and Ser to Ala (mutations C62A and S72A), and Lys to Arg (mutations K69R and 
K76R). The seven variants were first tested for cyclopropanation activity in cell lysate. 
Three of the variants, C62A, K69R, and K76R, were poorly expressed and not studied 
further. Two of the variants, H92N and H100N, gave improved total turnover numbers (1.2- 
and 1.4-fold improvement, respectively) for the formation of 2, while the remaining two 
failed to yield any improvements. Following this observation, we characterized the 
performance of the purified H92N and H100N variants and were pleased to observe similar 
enhancements in cyclopropanation activity. While purified BM3-HStar showed only modest 
conversion and poor selectivity, variants H92N and H100N in purified form gave much 
improved reaction yields and selectivities for cyclopropanation of 1 (Figure 7). Moreover, 
these two mutations could be recombined in a double variant H92N H100N that, as purified 
enzyme, afforded up to 560 TTN (0.1% enzyme loading, 1.8-fold improvement over BM3-
HStar) and 98:2 dr and 87% ee; selectivity numbers that are very close to those previously 
observed in reactions with whole cells expressing BM3-HStar (Scheme 1).
Next, we evaluated the performance of the new variants in whole-cell reactions, as the 
enzymes have hitherto provided superior performance when used as whole-cell catalysts. 
Gratifyingly, the improvement was even more significant (Figure 8). In particular, variant 
H92N H100N gave more than 20,000 TTN in the production of 2 (2.7-fold improvement 
over BM3-HStar), while maintaining the excellent diastereo- and enantioselectivity of the 
parent catalyst. Variants H92N, H100N, and H92N H100N express at similar levels to parent 
enzyme BM3-HStar (0.20–0.25 µM at OD600 = 10, see Supporting Information for 
determination of protein concentration in whole-cell suspension). Thus the observed 
increase in TTN translates to similar improvements in product/dry cell weight.
Finally, the improvement in activity imparted by mutations H92N and H100N could be 
generalized to other carbene transfer reactions, including styrene cyclopropanation and 
carbenoid insertion into the N–H bond of aniline (Figure S8). Under whole-cell reaction 
conditions, HStar H92N H100N yielded 55% and 30% increases in styrene 
cyclopropanation and aniline N–H insertion activities over unmutated BM3-HStar.
Characterization of BM3-HStar H92N H100N
Comparing the kinetics of formation of 2 with BM3-HStar and HStar H92N H100N under 
whole-cell reaction conditions at 10 mM substrate concentrations and ca. 0.2 µM enzyme 
concentration shows that the engineered variant supports faster product formation, but both 
rates decrease after ~ 30 min (Figure S9, Supporting Information). We performed similar 
inactivation analyses on BM3-HStar H92N H100N to find out whether the inactivation 
mechanism had changed. We noted changes in the CD spectral features upon treatment of 
ferrous BM3-HStar H92N H100N with EDA, similar to BM3-HStar (Figure S10, 
Supporting Information). In addition, bottom-up proteomic analyses indicated that residues 
K69, S72, K76, S89, K97, S304, and K306 of BM3-HStar H92N H100N were alkylated 
during the initial stages of this reaction, but no modification occurred at N92 or N100 
(Figure S11). Of these, only K69, S72, and K76 were observed to undergo modification in 
the parent enzyme BM3-HStar. Lastly, LC-MS analysis of purified BM3-HStar H92N 
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H100N after cyclopropanation showed that the porphyrin cofactor underwent identical 
alkylative modifications as in BM3-HStar.
Discussion
Various reports of irreversible inhibition of P450s by carbene precursors led us to investigate 
whether such pathways compete with productive catalysis in engineered “carbene 
transferases” derived from heme-containing proteins. This new enzyme activity involves a 
reactive intermediate that can damage the cofactor and protein if the carbene is not 
efficiently transferred to the substrate. Mutations to the protein sequence could assist 
productive catalysis, either by promoting productive transfer through improved binding and 
orientation of the substrate or by disfavoring non-productive transfer to the protein itself. 
Evolution finds both types of solutions by molding the protein active site and dynamics to 
promote productive catalysis, even when highly reactive species are generated during the 
catalytic cycle. Native P450 reactions that go through Compound I provide an excellent 
example of how an enzyme can generate a highly reactive species and direct it (most of the 
time) to a substrate. In contrast to P450-catalyzed monooxygenations, however, the newly-
developed carbene transfer activities of heme proteins have not yet been highly tuned by 
evolution. We are starting to investigate opportunities for enhancing this non-natural activity 
by directed evolution1 and rational engineering based on understanding some of the failure 
modes.
We found that the heme cofactor and several nucleophilic residues are modified by transfer 
of the reactive carbene to the enzyme rather than the olefin substrate during 
cyclopropanation of phenylacrylamide with EDA. Up to three additions of ethyl acetylidene 
fragment on the porphyrin were observed, and spectroscopic analysis of the modified 
porphyrin species suggests the formation of N-alkylporphyrin products. Presumably, this 
modification also interferes with metal binding, leading to the expulsion of Fe3+ as seen in 
the mass spectrum. These results suggest erosion of the active heme species, eventually 
leading to complete loss of the cofactor and catalytic function. Similar cofactor loss during 
reactions with other heme protein-based catalysts (myoglobin and a Ser-ligated P450) 
suggests that this off-cycle reaction is an inherent feature of porphyrin-based protein 
catalysts of carbene transfer reactions.
We also obtained evidence that carbenoid formation can result in the modification of protein 
side chains and disruption of BM3-HStar secondary structure. The observation of multiply 
modified species in the proteomic analyses implies that BM3-HStar is still capable of 
reacting with EDA even after initial modification. However, the iron carbenoid species might 
possess increasingly diminished reactivity and/or selectivity for productive cyclopropane 
formation due to the cumulative effects of protein structural modifications, accounting for 
the observed erosion in selectivity of BM3-HStar at high substrate concentrations and during 
pre-incubation with EDA.
We reasoned that reducing the nucleophilicity of some of the modified residues could reduce 
protein damage and possibly lead to better secondary structure preservation during the 
reaction and less inactivation. We identified two beneficial mutations, H92N and H100N, 
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that improve carbene transfer activity and selectivity. That BM3-HStar double mutant H92N 
H100N performed better in other types of carbene transfer reactions—styrene 
cyclopropanation and N–H insertion—indicates that the improvements are general rather 
than specific to substrate 1. A possible explanation for the effects of the mutations is that the 
reaction ensemble contains more active form of the enzyme. BM3-HStar H92N H100N, 
however, still undergoes irreversible inactivation: even though the mutations avert potentially 
deleterious modification at residues 92 and 100, the reactive iron carbenoid species 
nonetheless inflicts alkylative damage on the porphyrin and other nucleophilic residues, 
including several that did not appear to be alkylated in BM3-HStar. It remains to be seen 
whether further protein engineering, including directed evolution, can generate an enzyme 
that better directs the reactive carbenoid intermediate to reaction with the second substrate, 
as the native cytochrome P450 does with its highly reactive oxygen intermediates during the 
native reaction.
Our results indicate that EDA-induced inactivation is operative in reactions with purified 
enzyme and whole-cell catalyst. Yet, the relative rates of inactivation are strikingly different, 
with purified enzyme suffering much more rapid inactivation as well as inferior initial 
activity and selectivity. The origins of this difference are not yet clear, but several possible 
explanations can be put forth. One is that cellular components contribute to higher enzyme 
stability through the protective effects of, for example, molecular chaperones21, 
macromolecular crowding22, or even cytoplasmic molecules acting as sacrificial carbene 
acceptors. His-ligated heme proteins such as the globins are also known to undergo heme 
exchange and dissociation;23 heme exchange in the cell could replenish the cofactor and 
prolong the lifetime of the catalyst. Finally, it is possible that the rate of inactivation depends 
on the protein fold or family, and future studies will investigate the robustness of different 
heme protein scaffolds for carbene transfer reactions.
Conclusions
Exploiting the ability of proteins to evolve and adapt to new challenges, our laboratory has 
developed variants of P450-BM3 as platforms for non-natural reactions with xenobiotic 
diazo compounds. However, introduction of xenobiotic reagents to natural enzymes can lead 
to undesired repercussions such as inactivation.7 We have provided clear evidence for 
mechanism-based inactivation of a His-ligated P450-BM3 variant by ethyl diazoacetate that 
results in the modification of the heme prosthetic group and several protein side chains, 
which degrades enzyme performance and causes irreversible activity loss. Site-directed 
mutagenesis of some of the affected residues to amino acids that are less easily modified 
created superior variants with improved cyclopropanation activity as both purified enzymes 
and whole-cell catalysts.
An alternate approach to optimization of enzymes for non-natural reactions would be to 
accumulate beneficial mutations by random mutagenesis and high throughput screening 
(classical directed evolution). However, screening can be challenging for some reactions, 
especially when high enantioselectivity is desired. For this reason, directed evolution to date 
has focused on active site residues defined for the wild type enzyme. However, this approach 
places little consideration on the potential incompatibility of the xenobiotic reagents with 
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biological systems, which could render the enzyme susceptible to harmful off-cycle 
reaction(s). Tracing the catalyst’s fate during the reaction enables the identification of such 
inactivation “hotspots”, and allows for the discovery of beneficial mutations at more distant 
residues. Echoing a recent report on mitigation of substrate inhibition in a DERA enzyme,7c 
our results demonstrate the merits of mechanistic analyses in improving the overall activity 
of enzymes for biotechnological applications, especially ones that are employed in non-
native environments. Given the growing interest in the development of biocatalytic carbene 
transfer reactions, we expect that the inactivation profiling and rational engineering approach 
we outline here will be generally useful for creating “carbene transferases” with improved 
lifetimes and tolerance to reaction conditions for synthetic applications.
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Figure 1. 
A. Proposed catalytic cycle for heme protein-catalyzed carbene transfer to an olefin starts 
from the reduced ferrous state, which undergoes reaction with a diazo compound to form the 
putative iron carbenoid. The carbenoid reacts with an olefin, forming the cyclopropane 
product and regenerating the ferrous heme protein. B. Proposed mechanism-based 
inactivation via (a) porphyrin and (b) side chain modification involving the same iron 
carbenoid intermediate that mediates productive olefin cyclopropanation.
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Figure 2. 
LC-MS monitoring of heme content of the reaction mixture (MWD set at 330 nm) at 
different reaction times: amount of unmodified heme decreases during the course of the 
reaction, and new species appear.
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Figure 3. 
Inset: Electronic absorption spectrum of porphyrin isolated after the cyclopropanation 
reaction as the Zn-complexed form indicates modification; spectrum of Zn-PPIX standard is 
provided for comparison. High-resolution mass spectrometry (HRMS) analysis of modified 
porphyrin isolated after the cyclopropanation reaction, showing major peaks with m/z of 
735.3378 and 821.3753, which correspond to multiple additions of C4H6O2 fragment.
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Figure 4. 
Circular dichroism (CD) spectra of ferrous BM3-HStar before (black) and after reaction 
with EDA (blue). Decrease in molar ellipticity at 222 nm suggests a change in the secondary 
structure after the reaction, specifically a decrease in α-helical content and an increase in 
random coil.
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Figure 5. 
Representative LC-MS/MS analysis of peptide fragments from crude cyclopropanation 
mixture. Modified peptides from inactivated BM3-HStar were analyzed using mass 
spectrometry after incubation with Na2S2O4, EDA and 1 for 5 s. The modified residue is 
highlighted in orange. For complete LC-MS/MS traces of peptide fragments from the 
reaction mixture, see Figure S6 (Supplementary Information).
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Figure 6. 
Location of alkylated residues relative to the heme cofactor as mapped onto WT BM3 
crystal structure (PDB ID: 2IJ2). Measured distances to the Fe center (in parentheses) are 
determined based on the WT BM3 crystal structure.
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Figure 7. 
Site-directed mutagenesis of BM3-HStar to improve yield and selectivity of 
cyclopropanation of acrylamide 1 with EDA. Reactions were performed with 10 µM 
enzyme, 10 mM of 1, 20 mM of EDA, and 10 mM of Na2S2O4 in 100 mM KPi buffer (pH = 
8.0). Yields and diastereoselectivity were determined by GC calibrated for 2. 
Enantioselectivity was determined by chiral SFC (See Supporting Information for GC yield 
determination).
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Figure 8. 
Total turnover numbers (TTNs) for cyclopropanation of 1 with whole cells expressing BM3-
HStar variants. Reactions were performed with whole cells expressing the enzyme 
(resuspended in M9-N media to OD600 = 10), 10 mM of 1, and 20 mM of EDA. TTN = 
[product]/[enzyme]; enzyme concentration in whole-cell suspension was determined by 
ferrous expression assay (See Supporting Information for assay procedure); product 
concentration at the end of the reaction was determined by GC calibrated for 2.
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Scheme 1. 
Observed erosion in yield and enantioselectivity of cyclopropanation with BM3-HStar in 
whole E. coli cells at high substrate concentrations.
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